CONTACT US
Home > APIs> > Silodosin
160970-54-7-Silodosin Silodosin

Silodosin

For research use only. Not for therapeutic Use.

  • CAT Number: A000383
  • CAS Number: 160970-54-7
  • Molecular Formula: C25H32F3N3O4
  • Molecular Weight: 495.5
  • Purity: ≥95%
Inquiry Now
Related Small Molecules: Anastrozole     Linezolid     Dextromethorphan hydrobromide hydrate    

Silodosin is an α1-adrenoceptor antagonist approved for the symptomatic treatment of benign prostatic hyperplasia. It acts as an α1-adrenoceptor antagonist with high uroselectivity (selectivity for the prostate). Since silodosin has high affinity for the α1A adrenergic receptor, it causes practically no orthostatic hypotension (in contrast to other α1 blockers). On the other side, the high selectivity seems to be the cause of silodosin/’s typical side effect of retrograde ejaculation.


Catalog Number A000383
CAS Number 160970-54-7
Synonyms

160970-54-7; Rapaflo; Urief; Silodyx; Urorec

Molecular Formula C25H32F3N3O4
Purity ≥95%
Target Neuronal Signaling
Solubility Soluble in DMSO > 10 mM
Storage -20°C
InChI 1S/C25H32F3N3O4/c1-17(30-8-12-34-21-5-2-3-6-22(21)35-16-25(26,27)28)13-18-14-19-7-10-31(9-4-11-32)23(19)20(15-18)24(29)33/h2-3,5-6,14-15,17,30,32H,4,7-13,16H2,1H3,(H2,29,33)/t17-/m1/s1
InChIKey PNCPYILNMDWPEY-QGZVFWFLSA-N
SMILES CC(CC1=CC2=C(C(=C1)C(=O)N)N(CC2)CCCO)NCCOC3=CC=CC=C3OCC(F)(F)F
Reference

1: Patil SB, Ranka K, Kundargi VS, Guru N. Comparison of tamsulosin and silodosin
in the management of acute urinary retention secondary to benign prostatic
hyperplasia in patients planned for trial without catheter. A prospective
randomized study. Cent European J Urol. 2017;70(3):259-263. doi:
10.5173/ceju.2017.1313. Epub 2017 Jun 29. PubMed PMID: 29104788; PubMed Central
PMCID: PMC5656367.
<br>

2: Elgalaly H, Eliwa A, Seleem M, Salem E, Omran M, Shello H, Abdelwahab K,
Khalil S, Kamel M. Silodosin in the treatment of distal ureteric stones in
children: A prospective, randomised, placebo-controlled study. Arab J Urol. 2017
Jul 12;15(3):194-198. doi: 10.1016/j.aju.2017.05.005. eCollection 2017 Sep.
PubMed PMID: 29071151; PubMed Central PMCID: PMC5651944.

<br>
3: Choi WS, Cho MC, Lee JW, Song SH, Oh JK, Lee SW, Cho SY, Park JY. Efficacy and
safety of silodosin in the treatment of lower urinary tract symptoms in elderly
men taking antihypertensive medications. Prostate Int. 2017 Sep;5(3):113-118.
doi: 10.1016/j.prnil.2017.02.001. Epub 2017 Feb 20. PubMed PMID: 28828355; PubMed
Central PMCID: PMC5551694.
<br>

4: Fukuhara S. Editorial Comment to Silodosin versus naftopidil in the treatment
of premature ejaculation: A prospective multicenter trial. Int J Urol. 2017
Aug;24(8):631. doi: 10.1111/iju.13418. Epub 2017 Jul 21. PubMed PMID: 28733993.
<br>

5: Manohar CMS, Nagabhushana M, Karthikeyan VS, Sanjay RP, Kamath AJ,
Keshavamurthy R. Safety and efficacy of tamsulosin, alfuzosin or silodosin as
monotherapy for LUTS in BPH – a double-blind randomized trial. Cent European J
Urol. 2017 Jun 30;70(2):148-153. doi: 10.5173/ceju.2017.924. Epub 2017 Jun 7.
PubMed PMID: 28721281; PubMed Central PMCID: PMC5510335.
<br>

6: Tanaka Y, Tanuma Y, Masumori N. The Persistence of Silodosin Monotherapy and
the Reasons for Withdrawal from Treatment of Previously Untreated Japanese
Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic
Hyperplasia. Adv Urol. 2017;2017:4842025. doi: 10.1155/2017/4842025. Epub 2017
Jun 13. PubMed PMID: 28694823; PubMed Central PMCID: PMC5485276.
<br>

7: Shah PA, Shrivastav PS. Determination of silodosin and its active glucuronide
metabolite KMD-3213G in human plasma by LC-MS/MS for a bioequivalence study.
Biomed Chromatogr. 2017 Jul 3. doi: 10.1002/bmc.4041. [Epub ahead of print]
PubMed PMID: 28670733.

<br>
8: Chatterjee S, Agrawal D. Silodosin-associated intraoperative floppy iris
syndrome. Indian J Ophthalmol. 2017 Jun;65(6):538-539. doi:
10.4103/ijo.IJO_704_16. PubMed PMID: 28643727; PubMed Central PMCID: PMC5508473.

<br>
9: Sato Y, Otani T, Amano T, Araki T, Kondou N, Matsukawa M, Tobe M, Haga K,
Uchida K, Honma I. Silodosin versus naftopidil in the treatment of premature
ejaculation: A prospective multicenter trial. Int J Urol. 2017 Aug;24(8):626-631.
doi: 10.1111/iju.13392. Epub 2017 Jun 18. PubMed PMID: 28627033.

<br>
10: Celik S, Akdeniz F, Yildirim MA, Bozkurt O, Bulut MG, Hacihasanoglu ML, Demir
O. Computed tomography findings predicting the success of silodosin for medical
expulsive therapy of ureteral stones. Kaohsiung J Med Sci. 2017
Jun;33(6):290-294. doi: 10.1016/j.kjms.2017.04.001. Epub 2017 May 3. PubMed PMID:
28601233.

Request a Quote